Recruiting

Testing a new antibody treatment for life-threatening heart failure with shock

Plain-English translation of NCT06832722 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new medication called invobenitug (also known as procizumab) to see if it can safely treat cardiogenic shock, a critical condition where your heart suddenly cannot pump enough blood to your body. Cardiogenic shock is life-threatening and happens when the heart fails dramatically, often after a heart attack or severe heart disease. This trial will check whether the medication is safe, how your body processes it, and whether it helps patients survive and recover.

Cardiogenic shock kills many patients even with current treatments. Doctors need new options to help the heart pump blood more effectively and save more lives. This medication targets a specific marker found in patients with this condition, offering hope for a new way to treat this medical emergency.

Do you qualify?

You likely qualify if…

you have been diagnosed with cardiogenic shock requiring medications to support your blood pressure
you have high levels of a specific marker (cDPP3) in your blood that this treatment targets
your shock is caused by a heart attack, sepsis, or heart failure—not another condition
you are between 18 and 80 years old
you were admitted to the ICU less than 24 hours before joining the trial
you have given signed informed consent to participate

You likely don't qualify if…

you have been on blood pressure support medications for more than 16 hours before enrollment
you have had a recent stroke or mini-stroke in the last 3 months
you are taking certain medications like angiotensin II or levosimendan
you have severe liver disease, severe lung disease, severe kidney disease, or other serious chronic conditions
you weigh more than 120 kg (or 150 kg if in the US)

What participation looks like

You will be randomly assigned to receive either the new medication invobenitug or a placebo (inactive treatment) as an injection. The study will closely monitor your heart function, blood work, and overall safety over time. Researchers will measure how your body processes the medication and whether it helps improve your condition—all while you receive standard medical care for your shock in the intensive care unit.

AI-generated summary from trial data · Jul 19, 2026 · Not medical advice

Trial locations(25 sites)

Armenia

Yerevan medical scientific center, Yerevan

Erebouni Mwdical Center, Yerevan

Belgium

Heart Center Aalst, AZORG, Aalst

University Hospital Saint Pierre, Brussels

Ghent University Hospital, Ghent